Immunosuppressive and anti-inflammatory properties of engineered nanomaterials

British Journal of Pharmacology

Volumn 171, Issue 17, 2014, Pages 3988-4000

  Ilinskaya, A N ^a   Dobrovolskaia, M A ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

anti inflammatory properties; immune inhibition; immune system; immunosuppression; inflammation; nanoparticles

Indexed keywords

ANTIINFLAMMATORY AGENT; BETAMETHASONE SODIUM PHOSPHATE; BUTYRIC ACID; CELASTROL; CERIUM OXIDE; CHITOSAN; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DENDRIMER; DEXAMETHASONE; DNA VACCINE; GLUCOSAMINE; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; LIPOSOME; MACROGOL; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; MYCOPHENOLIC ACID; NANOMATERIAL; NANOPARTICLE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYGLACTIN; POLYLACTIC ACID; RAPAMYCIN; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TACROLIMUS; UNINDEXED DRUG;

ANEMIA; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CELLULAR IMMUNITY; DENDRITIC CELL; DIARRHEA; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG TARGETING; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INJECTION SITE REACTION; KIDNEY INJURY; LEUKOPENIA; LIPOSOMAL DELIVERY; NANOENGINEERING; NANOTECHNOLOGY; NAUSEA; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SKIN DISEASE; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VOMITING; ANIMAL; CHEMICAL PHENOMENA; CHEMISTRY; DRUG EFFECTS; IMMUNE SYSTEM; IMMUNOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; NANOSTRUCTURES;

EID: 84906058627     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12722     Document Type: Review

References (135)

1. Abbas KA, Lichman AH, Pillai S, (2012). Cellular and Molecular Immunology, 7th edn. Elsevier Saunders: Philadelphia, PA.
2. Agnihotri SM, Vavia PR, (2009). Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine 5: 90-95.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic receptors. Br J Pharmacol 170: 1676-1705.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
6. Alving CR, Swartz GM Jr, Wassef NM, Ribas JL, Herderick EE, Virmani R, et-al. (1996). Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation. J Lab Clin Med 127: 40-49.
7. Anderson R, Franch A, Castell M, Perez-Cano FJ, Bräuer R, Pohlers D, et-al. (2010). Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis. Arthritis Res Ther 12: R147.
8. 2 and ZnO nanoparticles on human lymphocytes, dendritic cells and exosome production. Toxicol Appl Pharmacol 264: 94-103.
9. Azzi J, Tang L, Moore R, Tong R, El Haddad N, Akiyoshi T, et-al. (2010). Polylactide-cyclosporin A nanoparticles for targeted immunosuppression. FASEB J 24: 3927-3938.
10. Barata TS, Teo I, Brocchini S, Zloh M, Shaunak S, (2011). Partially glycosylated dendrimers block MD-2 and prevent TLR4-MD-2-LPS complex mediated cytokine responses. PLoS Comput Biol 7: e1002095.
11. Basarkar A, Singh J, (2009). Poly (lactide-co-glycolide)-polymethacrylate nanoparticles for intramuscular delivery of plasmid encoding interleukin-10 to prevent autoimmune diabetes in mice. Pharm Res 26: 72-81.
12. Baschong W, Wrigley NG, (1990). Small colloidal gold conjugated to Fab fragments or to immunoglobulin G as high-resolution labels for electron microscopy: a technical overview. J Electron Microsc Tech 14: 313-323.
13. Beissert S, Schwarz A, Schwarz T, (2006). Regulatory T cells. J Invest Dermatol 126: 15-24.
14. Blank F, Gerber P, Rothen-Rutishauser B, Sakulkhu U, Salaklang J, De Peyer K, et-al. (2011). Biomedical nanoparticles modulate specific CD4+ T cell stimulation by inhibition of antigen processing in dendritic cells. Nanotoxicology 5: 606-621.
15. Boraschi D, Costantino L, Italiani P, (2012). Interaction of nanoparticles with immunocompetent cells: nanosafety considerations. Nanomedicine (Lond) 7: 121-131.
16. Boridy S, Soliman GM, Maysinger D, (2012). Modulation of inflammatory signaling and cytokine release from microglia by celastrol incorporated into dendrimer nanocarriers. Nanomedicine (Lond) 7: 1149-1165.
17. Bottiger Y, Brattstrom C, Tyden G, Sawe J, Groth CG, (1999). Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol 48: 445-448.
18. Bregoli L, Chiarini F, Gambarelli A, Sighinolfi G, Gatti AM, Santi P, et-al. (2009). Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines. Toxicology 262: 121-129.
19. Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E, (2010). mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant 24: 149-156
20. Canadas O, Guerrero R, Garcia-Canero R, Orellana G, Menendez M, Casals C, (2004). Characterization of liposomal tacrolimus in lung surfactant-like phospholipids and evaluation of its immunosuppressive activity. Biochemistry 43: 9926-9938.
21. Castelli F, Puglia C, Sarpietro MG, Rizza L, Bonina F, (2005). Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry. Int J Pharm 304: 231-238.
22. Chandrasekar D, Sistla R, Ahmad FJ, Khar RK, Diwan PV, (2007). The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats. Biomaterials 28: 504-512.
23. Chauhan AS, Jain NK, Diwan PV, Khopade AJ, (2004). Solubility enhancement of indomethacin with poly(amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats. J Drug Target 12: 575-583.
24. Chauhan AS, Diwan PV, Jain NK, Tomalia DA, (2009). Unexpected in vivo anti-inflammatory activity observed for simple, surface functionalized poly(amidoamine) dendrimers. Biomacromolecules 10: 1195-1202.
25. Chen YC, Lo CL, Lin YF, Hsiue GH, (2013). Rapamycin encapsulated in dual-responsive micelles for cancer therapy. Biomaterials 34: 1115-1127.
26. Chen YW, Hwang KC, Yen CC, Lai YL, (2004). Fullerene derivatives protect against oxidative stress in RAW 264.7 cells and ischemia-reperfused lungs. Am J Physiol Regul Integr Comp Physiol 287: R21-R26.
27. Cheng Y, Man N, Xu T, Fu R, Wang X, Wen L, (2007). Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers. J Pharm Sci 96: 595-602.
28. Cooper DL, Harirforoosh S, (2014). Design and optimization of PLGA-based diclofenac loaded nanoparticles. PLoS ONE 9: e87326.
29. Czogalla A, (2009). Oral cyclosporine A-the current picture of its liposomal and other delivery systems. Cell Mol Biol Lett 14: 139-152.
30. Dernedde J, Rausch A, Weinhart M, Enders S, Tauber R, Licha K, et-al. (2010). Dendritic polyglycerol sulfates as multivalent inhibitors of inflammation. Proc Natl Acad Sci U S A 107: 19679-19684.
31. Descotes J, (2004). Importance of immunotoxicity in safety assessment: a medical toxicologist's perspective. Toxicol Lett 149: 103-108.
32. Descotes J, (2012). Safety immunopharmacology: evaluation of the adverse potential of pharmaceuticals on the immune system. J Pharmacol Toxicol Methods 66: 79-83.
33. Dianzani C, Cavalli R, Zara GP, Gallicchio M, Lombardi G, Gasco MR, et-al. (2006). Cholesteryl butyrate solid lipid nanoparticles inhibit adhesion of human neutrophils to endothelial cells. Br J Pharmacol 148: 648-656.
34. Dietert RR, (2011). Role of developmental immunotoxicity and immune dysfunction in chronic disease and cancer. Reprod Toxicol 31: 319-326.
35. Dobrovolskaia MA, Kozlov SV, (2005). Inflammation and cancer: when NF-kappaB amalgamates the perilous partnership. Curr Cancer Drug Targets 5: 325-344.
36. Dobrovolskaia MA, McNeil SE, (2007). Immunological properties of engineered nanomaterials. Nat Nanotechnol 2: 469-478.
37. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE, (2008). Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 5: 487-495.
38. Dobrovolskaia MA, Germolec DR, Weaver JL, (2009). Evaluation of nanoparticle immunotoxicity. Nat Nanotechnol 4: 411-414.
39. Dobrovolskaia MA, Patri AK, Potter TM, Rodriguez JC, Hall JB, McNeil SE, (2012). Dendrimer-induced leukocyte procoagulant activity depends on particle size and surface charge. Nanomedicine (Lond) 7: 245-256.
40. Dye D, Watkins J, (1980). Suspected anaphylactic reaction to Cremophor EL. Br Med J 280: 1353.
41. Elsabahy M, Wooley KL, (2013). Cytokines as biomarkers of nanoparticle immunotoxicity. Chem Soc Rev 42: 5552-5576.
42. Erdogan M, Wright JR Jr, McAlister VC, (2002). Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. Br J Dermatol 146: 964-967.
43. Freise CE, Liu T, Hong K, Osorio RW, Papahadjopoulos D, Ferrell L, et-al. (1994). The increased efficacy and decreased nephrotoxicity of a cyclosporine liposome. Transplantation 57: 928-932.
44. Getts DR, Shankar S, Chastain EM, Martin A, Getts MT, Wood K, et-al. (2011). Current landscape for T-cell targeting in autoimmunity and transplantation. Immunotherapy 3: 853-870.
45. Getts DR, Martin AJ, McCarthy DP, Terry RL, Hunter ZN, Yap WT, et-al. (2012). Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol 30: 1217-1224.
46. Ghanbarzadeh S, Arami S, Pourmoazzen Z, Khorrami A, (2013). Improvement of the antiproliferative effect of rapamycin on tumor cell lines by poly (monomethylitaconate)-based pH-sensitive, plasma stable liposomes. Colloids Surf B Biointerfaces 115C: 323-330.
47. Gibaud S, Andreux JP, Weingarten C, Renard M, Couvreur P, (1994). Increased bone marrow toxicity of doxorubicin bound to nanoparticles. Eur J Cancer 30A: 820-826.
48. Goldmann K, Ensminger SM, Spriewald BM, (2012). Oral gene application using chitosan-DNA nanoparticles induces transferable tolerance. Clin Vaccine Immunol 19: 1758-1764.
49. Gref R, Quellec P, Sanchez A, Calvo P, Dellacherie E, Alonso MJ, (2001). Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers. Eur J Pharm Biopharm 51: 111-118.
50. Guadagnini R, Halamoda Kenzaoui B, Cartwright L, Pojana G, Magdolenova Z, Bilanicova D, et-al. (2013). Toxicity screenings of nanomaterials: challenges due to interference with assay processes and components of classic in vitro tests. Nanotoxicology. doi: 10.3109/17435390.2013.829590.
51. Hanley C, Thurber A, Hanna C, Punnoose A, Zhang J, Wingett DG, (2009). The Influences of cell type and ZnO nanoparticle size on immune cell cytotoxicity and cytokine induction. Nanoscale Res Lett 4: 1409-1420.
52. Hawkins MJ, Soon-Shiong P, Desai N, (2008). Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60: 876-885.
53. Hayder M, Poupot M, Baron M, Nigon D, Turrin CO, Caminade AM, et-al. (2011). A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis. Sci Transl Med 3: 81ra35.
54. Hirst SM, Karakoti AS, Tyler RD, Sriranganathan N, Seal S, Reilly CM, (2009). Anti-inflammatory properties of cerium oxide nanoparticles. Small 5: 2848-2856.
55. Horisawa E, Kubota K, Tuboi I, Sato K, Yamamoto H, Takeuchi H, et-al. (2002). Size-dependency of DL-lactide/glycolide copolymer particulates for intra-articular delivery system on phagocytosis in rat synovium. Pharm Res 19: 132-139.
56. Howard KA, Paludan SR, Behlke MA, Besenbacher F, Deleuran B, Kjems J, (2009). Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther 17: 162-168.
57. Hu J, Cheng Y, Ma Y, Wu Q, Xu T, (2009). Host-guest chemistry and physicochemical properties of the dendrimer-mycophenolic acid complex. J Phys Chem B 113: 64-74.
58. Ilinskaya AN, Man S, Patri AK, Clogston JD, Crist RM, Cachau RE, et-al. (2013). Inhibition of phosphoinositol 3 kinase contributes to nanoparticle-mediated exaggeration of endotoxin-induced leukocyte procoagulant activity. Nanomedicine (Lond). doi: 10.2217/NNM.13.137; [Epub ahead of print].
59. Ishihara T, Izumo N, Higaki M, Shimada E, Hagi T, Mine L, et-al. (2005). Role of zinc in formulation of PLGA/PLA nanoparticles encapsulating betamethasone phosphate and its release profile. J Control Release 105: 68-76.
60. Ishihara T, Kubota T, Choi T, Higaki M, (2009). Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate. J Pharmacol Exp Ther 329: 412-417.
61. Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Kumar MN, (2007). PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J Control Release 119: 197-206.
62. Ivanov S, Dragoi AM, Wang X, Dallacosta C, Louten J, Musco G, et-al. (2007). A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110: 1970-1981.
63. Jensen LB, Magnussson E, Gunnarsson L, Vermehren C, Nielsen HM, Petersson K, (2010). Corticosteroid solubility and lipid polarity control release from solid lipid nanoparticles. Int J Pharm 390: 53-60.
64. John AE, Lukacs NW, Berlin AA, Palecanda A, Bargatze RF, Stoolman LM, et-al. (2003). Discovery of a potent nanoparticle P-selectin antagonist with anti-inflammatory effects in allergic airway disease. FASEB J 17: 2296-2298.
65. Kahan B, (2011). Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment. Expert Opin Drug Saf 10: 727-749.
66. Kao YY, Chen YC, Cheng TJ, Chiung YM, Liu PS, (2012). Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity. Toxicol Sci 125: 462-472.
67. Khandare J, Kolhe P, Pillai O, Kannan S, Lieh-Lai M, Kannan RM, (2005). Synthesis, cellular transport, and activity of polyamidoamine dendrimer-methylprednisolone conjugates. Bioconjug Chem 16: 330-337.
68. Khoury M, Louis-Plence P, Escriou V, Noel D, Largeau C, Cantos C, et-al. (2006). Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum 54: 1867-1877.
69. Kobayashi K, Kaneda K, Kasama T, (2001). Immunopathogenesis of delayed-type hypersensitivity. Microsc Res Tech 53: 241-245.
70. Kolhe P, Misra E, Kannan RM, Kannan S, Lieh-Lai M, (2003). Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm 259: 143-160.
71. Kroll A, Pillukat MH, Hahn D, Schnekenburger J, (2012). Interference of engineered nanoparticles with in vitro toxicity assays. Arch Toxicol 86: 1123-1136.
72. Leuschner F, Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, Courties G, et-al. (2011). Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 29: 1005-1010.
73. Libutti SK, Paciotti GF, Byrnes AA, Alexander HR Jr, Gannon WE, Walker M, et-al. (2010). Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 16: 6139-6149.
74. Linker RA, Weller C, Luhder F, Mohr A, Schmidt J, Knauth M, et-al. (2008). Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations. Exp Neurol 211: 397-406.
75. Liu H, Wang Y, Li S, (2007). Advanced delivery of ciclosporin A: present state and perspective. Expert Opin Drug Deliv 4: 349-358.
76. Look M, Stern E, Wang QA, DiPlacido LD, Kashgarian M, Craft J, et-al. (2013). Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice. J Clin Invest 123: 1741-1749.
77. Look M, Saltzman WM, Craft J, Fahmy TM, (2014). The nanomaterial- dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus. Biomaterials 35: 1089-1095.
78. Lucarelli M, Gatti AM, Savarino G, Quattroni P, Martinelli L, Monari E, et-al. (2004). Innate defence functions of macrophages can be biased by nano-sized ceramic and metallic particles. Eur Cytokine Netw 15: 339-346.
79. Ma JS, Kim WJ, Kim JJ, Kim TJ, Ye SK, Song MD, et-al. (2010). Gold nanoparticles attenuate LPS-induced NO production through the inhibition of NF-kappaB and IFN-beta/STAT1 pathways in RAW264.7 cells. Nitric Oxide 23: 214-219.
80. Matsuo Y, Ishihara T, Ishizaki J, Miyamoto K, Higaki M, Yamashita N, (2009). Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell Immunol 260: 33-38.
81. Merk HF, Sachs B, Baron J, (2001). The skin: target organ in immunotoxicology of small-molecular-weight compounds. Skin Pharmacol Appl Skin Physiol 14: 419-430.
82. Metselaar JM, Wauben MH, Wagenaar-Hilbers JP, Boerman OC, Storm G, (2003). Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum 48: 2059-2066.
83. Milkova V, Kamburova K, Radeva T, (2013). Nanocolloids of indomethacin prepared using sonication and subsequent encapsulation with polysaccharide films. Colloids Surf B Biointerfaces 108: 279-284.
84. Mitchell LA, Lauer FT, Burchiel SW, McDonald JD, (2009). Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in mice. Nat Nanotechnol 4: 451-456.
85. Mitragotri S, Yoo JW, (2011). Designing micro- and nano-particles for treating rheumatoid arthritis. Arch Pharm Res 34: 1887-1897.
86. Moon EY, Yi GH, Kang JS, Lim JS, Kim HM, Pyo S, (2011). An increase in mouse tumor growth by an in vivo immunomodulating effect of titanium dioxide nanoparticles. J Immunotoxicol 8: 56-67.
87. Muller RH, Runge SA, Ravelli V, Thunemann AF, Mehnert W, Souto EB, (2008). Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm 68: 535-544.
88. Na M, Yiyun C, Tongwen X, Yang D, Xiaomin W, Zhenwei L, et-al. (2006). Dendrimers as potential drug carriers. Part II. Prolonged delivery of ketoprofen by in vitro and in vivo studies. Eur J Med Chem 41: 670-674.
89. Nel A, Xia T, Madler L, Li N, (2006). Toxic potential of materials at the nanolevel. Science 311: 622-627.
90. Paavola A, Kilpelainen I, Yliruusi J, Rosenberg P, (2000). Controlled release injectable liposomal gel of ibuprofen for epidural analgesia. Int J Pharm 199: 85-93.
91. Pantic I, (2011). Nanoparticles and modulation of immune responses. Sci Prog 94 (Pt 1): 97-107.
92. Park J, Gao W, Whiston R, Strom TB, Metcalfe S, Fahmy TM, (2011). Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. Mol Pharm 8: 143-152.
93. Park JS, Yang HN, Jeon SY, Woo DG, Kim MS, Park KH, (2012). The use of anti-COX2 siRNA coated onto PLGA nanoparticles loading dexamethasone in the treatment of rheumatoid arthritis. Biomaterials 33: 8600-8612.
94. Perkins WR, Vaughan DE, Plavin SR, Daley WL, Rauch J, Lee L, et-al. (1997). Streptokinase entrapment in interdigitation-fusion liposomes improves thrombolysis in an experimental rabbit model. Thromb Haemost 77: 1174-1178.
95. Pople PV, Singh KK, (2012). Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis-Part II: in vivo assessment of dermatopharmacokinetics, biodistribution and efficacy. Int J Pharm 434: 70-79.
96. Qu G, Zhang C, Yuan L, He J, Wang Z, Wang L, et-al. (2012). Quantum dots impair macrophagic morphology and the ability of phagocytosis by inhibiting the Rho-associated kinase signaling. Nanoscale 4: 2239-2244.
97. Quintana FJ, Murugaiyan G, Farez MF, Mitsdoerffer M, Tukpah AM, Burns EJ, et-al. (2010). An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 107: 20768-20773.
98. Rele SM, Cui W, Wang L, Hou S, Barr-Zarse G, Tatton D, et-al. (2005). Dendrimer-like PEO glycopolymers exhibit anti-inflammatory properties. J Am Chem Soc 127: 10132-10133.
99. Rouf MA, Vural I, Renoir JM, Hincal AA, (2009). Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells. J Liposome Res 19: 322-331.
100. Sakai T, Ishihara T, Higaki M, Akiyama G, Tsuneoka H, (2011). Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 52: 1516-1521.
101. Scheinman RI, Trivedi R, Vermillion S, Kompella UB, (2011). Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model. Nanomedicine (Lond) 6: 1669-1682.
102. Schmidt J, Metselaar JM, Wauben MH, Toyka KV, Storm G, Gold R, (2003). Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 126 (Pt 8): 1895-1904.
103. Schweingruber N, Haine A, Tiede K, Karabinskaya A, van den Brandt J, Wust S, et-al. (2011). Liposomal encapsulation of glucocorticoids alters their mode of action in the treatment of experimental autoimmune encephalomyelitis. J Immunol 187: 4310-4318.
104. Scripture CD, Figg WD, Sparreboom A, (2006). Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol 4: 165-172.
105. Shah M, Edman MC, Janga SR, Shi P, Dhandhukia J, Liu S, et-al. (2013). A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjogren's syndrome. J Control Release 171: 269-279.
106. Shah NM, Parikh J, Namdeo A, Subramanian N, Bhowmick S, (2006). Preparation, characterization and in vivo studies of proliposomes containing Cyclosporine A. J Nanosci Nanotechnol 6: 2967-2973.
107. Shaunak S, Thomas S, Gianasi E, Godwin A, Jones E, Teo I, et-al. (2004). Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol 22: 977-984.
108. Shen CC, Wang CC, Liao MH, Jan TR, (2011). A single exposure to iron oxide nanoparticles attenuates antigen-specific antibody production and T-cell reactivity in ovalbumin-sensitized BALB/c mice. Int J Nanomedicine 6: 1229-1235.
109. Shen CC, Liang HJ, Wang CC, Liao MH, Jan TR, (2012). Iron oxide nanoparticles suppressed T helper 1 cell-mediated immunity in a murine model of delayed-type hypersensitivity. Int J Nanomedicine 7: 2729-2737.
110. Shin SB, Cho HY, Kim DD, Choi HG, Lee YB, (2010). Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. Eur J Pharm Biopharm 74: 164-171.
111. Shirali AC, Look M, Du W, Kassis E, Stout-Delgado HW, Fahmy TM, et-al. (2011). Nanoparticle delivery of mycophenolic acid upregulates PD-L1 on dendritic cells to prolong murine allograft survival. Am J Transplant 11: 2582-2592.
112. Srinath P, Vyas SP, Diwan PV, (2000). Preparation and pharmacodynamic evaluation of liposomes of indomethacin. Drug Dev Ind Pharm 26: 313-321.
113. Sumbayev VV, Yasinska IM, Garcia CP, Gilliland D, Lall GS, Gibbs BF, et-al. (2012). Gold nanoparticles downregulate interleukin-1beta-induced pro-inflammatory responses. Small 9: 472-477.
114. Szebeni J, (2005). Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216: 106-121.
115. Tammam S, Mathur S, Afifi N, (2012). Preparation and biopharmaceutical evaluation of tacrolimus loaded biodegradable nanoparticles for liver targeting. J Biomed Nanotechnol 8: 439-449.
116. Tang L, Azzi J, Kwon M, Mounayar M, Tong R, Yin Q, et-al. (2012). Immunosuppressive activity of size-controlled PEG-PLGA nanoparticles containing encapsulated cyclosporine A. J Transplant 2012: 896141.
117. Thomas TP, Goonewardena SN, Majoros IJ, Kotlyar A, Cao Z, Leroueil PR, et-al. (2011). Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis. Arthritis Rheum 63: 2671-2680.
118. Thomson AW, Turnquist HR, Raimondi G, (2009). Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9: 324-337.
119. Tsai CY, Lu SL, Hu CW, Yeh CS, Lee GB, Lei HY, (2012). Size-dependent attenuation of TLR9 signaling by gold nanoparticles in macrophages. J Immunol 188: 68-76.
120. Tsai S, Shameli A, Yamanouchi J, Clemente-Casares X, Wang J, Serra P, et-al. (2010). Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 32: 568-580.
121. Turker S, Erdogan S, Ozer YA, Bilgili H, Deveci S, (2008). Enhanced efficacy of diclofenac sodium-loaded lipogelosome formulation in intra-articular treatment of rheumatoid arthritis. J Drug Target 16: 51-57.
122. Ulmansky R, Turjeman K, Baru M, Katzavian G, Harel M, Sigal A, et-al. (2012). Glucocorticoids in nano-liposomes administered intravenously and subcutaneously to adjuvant arthritis rats are superior to the free drugs in suppressing arthritis and inflammatory cytokines. J Control Release 160: 299-305.
123. Van Beers MM, Gilli F, Schellekens H, Randolph TW, Jiskoot W, (2012). Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene. J Pharm Sci 101: 187-199.
124. Varma RK, Kaushal R, Junnarkar AY, Thomas GP, Naidu MU, Singh PP, et-al. (1985). Polysorbate 80: a pharmacological study. Arzneimittelforschung 35: 804-808.
125. Watanabe H, Nakanishi T, Umetsu M, Kumagai I, (2008). Human anti-gold antibodies: biofunctionalization of gold nanoparticles and surfaces with anti-gold antibodies. J Biol Chem 283: 36031-36038.
126. Whitmire RE, Wilson DS, Singh A, Levenston ME, Murthy N, Garcia AJ, (2012). Self-assembling nanoparticles for intra-articular delivery of anti-inflammatory proteins. Biomaterials 33: 7665-7675.
127. Windebank AJ, Blexrud MD, de Groen PC, (1994). Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther 268: 1051-1056.
128. Woo HN, Chung HK, Ju EJ, Jung J, Kang HW, Lee SW, et-al. (2012). Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy. Int J Nanomedicine 7: 2197-2208.
129. Yamashita K, Sakai M, Takemoto N, Tsukimoto M, Uchida K, Yajima H, et-al. (2009). Attenuation of delayed-type hypersensitivity by fullerene treatment. Toxicology 261: 19-24.
130. Yanez JA, Forrest ML, Ohgami Y, Kwon GS, Davies NM, (2008). Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon- caprolactone) micelles of rapamycin. Cancer Chemother Pharmacol 61: 133-144.
131. Yeste A, Nadeau M, Burns EJ, Weiner HL, Quintana FJ, (2012). Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 109: 11270-11275.
132. Yuan XB, Yuan YB, Jiang W, Liu J, Tian EJ, Shun HM, et-al. (2008). Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation. Int J Pharm 349: 241-248.
133. Zhang J, Smith E, (2011). Percutaneous permeation of betamethasone 17-valerate incorporated in lipid nanoparticles. J Pharm Sci 100: 896-903.
134. Zhang R, He R, Qian J, Guo J, Xue K, Yuan YF, (2010). Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Invest Ophthalmol Vis Sci 51: 3575-3582.
135. van Zuylen L, Verweij J, Sparreboom A, (2001). Role of formulation vehicles in taxane pharmacology. Invest New Drugs 19: 125-141.